Howmet Aerospace Inc vs Zimmer Biomet Holdings Inc — how do they compare? Howmet Aerospace Inc trades at $225.06 (market cap $88.76B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Howmet Aerospace Inc is far larger — about 5.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HWM | ZBH | |
|---|---|---|
Market Cap | $88.76B | $16.95B |
Volume | 2,648,516 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $292.65 | $103.98 |
52-Week Low | $184.09 | $79.58 |
Typical Hold Time | 35 Days | 89 Days |
Enterprise Value | $92.86B | $24.02B |
Dividend Yield | 0.25% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.55, up 1.28% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income are projected to grow in 2026, supported by robust demand in aerospace and defense. Analyst consensus is overwhelmingly bullish, with an 84% buy rating and a $328.10 price target, indicating significant upside potential from current levels.
The outlook for HWM is positive, driven by earnings growth and sector tailwinds, though technical indicators suggest near-term caution. Key risks include supply-chain pressures and competitive dynamics. Institutional interest remains strong, supporting the long-term investment case for shareholders focused on aerospace exposure.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →